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Abstract. Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is associated with distinct abnormalities
in brain function and structure. Here we discuss how future developments in functional, structural and nuclear brain imaging
may help us to better understand, diagnose, and potentially even treat PD. These new horizons may be reached by developing
tracers that specifically bind to alpha synuclein, by looking into different places in the body (such as the gut) or in smaller
cerebral nuclei (with improved spatial resolution), and by developing new approaches for quantifying and interpreting altered
dynamics in large-scale brain networks.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neu-
rodegenerative disorder characterized by motor
symptoms such as bradykinesia, rigidity and tremor,
and a large variety of non-motor symptoms. The
pathological hallmark of the disease is a profound
loss of nigro-striatal dopamine cells and an accumu-
lation of intracellular inclusions called Lewy bodies,
which are comprised of alpha-synuclein aggregates.
In concert with dopaminergic cell loss, several other
neurotransmitter systems also degenerate, and in later
stages Lewy body pathology also spreads to the cor-
tex. This makes PD a prototypical systems disorder,
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which can be fully understood only when investigat-
ing molecular, structural and functional abnormalities
at the level of brain networks [1, 2]. With the rise
of neuroscience in the last few decades, a plethora
of new methods and approaches have become avail-
able. In this paper, we review and speculate how
future developments in functional imaging, structural
imaging, and nuclear imaging can help us understand,
diagnose or even treat PD.
FUNCTIONAL IMAGING
Imaging of brain activity can be done with
functional magnetic resonance imaging (fMRI)
or positron emission tomography (PET). These
approaches have made significant contributions to
our understanding of the pathophysiology of PD.
The field has grown from focussing on abnormal,
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task-related activity in isolated brain regions (such
as the putamen) to demonstrating abnormal inter-
actions between intrinsic, large-scale networks in
patients with PD (such as the cortico-striatal circuit).
For example, a recent paper has demonstrated that
PD patients spend more time in “brain states” that
are characterized by increased interactions between
cerebral networks, at the expense of more sparsely
connected, segregated brain states [3]. The shift
from single brain regions to large-scale networks
comes with new difficulties: the data have become
multi-dimensional, and this makes it more difficult
to extract meaningful patterns. The challenge is to
extract biologically relevant parameters that capture
(dys)function of an entire network.
An existing approach that has been used for a
long time is the Parkinson’s Disease Related Pat-
tern (PDRP), i.e., a metabolic covariance pattern
(or network) that is specific to PD, and that can
be calculated using PET and fMRI data [2]. The
validity of this approach has been proven in dif-
ferent centres across the world, although it has not
been translated into standard clinical practice. This
is probably because it works best with PET, which
is not widely available. A second, more recently
developed approach to deal with multi-dimensional
data is the use of generative models, i.e., computa-
tional models that estimate how observed (fMRI) data
were generated, given a set of priors and hypotheses
regarding the configuration of the network [4]. This
approach, which is implemented in dynamic causal
modelling (DCM), has the advantage that different
competing models of brain function can be com-
pared within a group or between two groups (using
Bayesian model selection). In PD, DCM has been
used to test how network interactions give rise to
tremor and to (abnormal) voluntary actions [5–7].
Inter-individual differences in statistical evidence for
a particular model of brain function may be used
to define (and clinically validate) imaging-based PD
phenotypes, or even to support differential diagno-
sis through Bayesian model selection [4]. Finally, a
third approach is to extract biologically meaningful
features from multi-dimensional imaging data. For
example, using resting state fMRI data, parameters
can be calculated that reflect the gradient of cortico-
striatal connectivity across striatal subregions [8].
These parameters (such as the direction and steep-
ness of the gradient) are biologically meaningful,
because they reflect the underlying anatomy and dis-
tribution of dopamine. Also, they may be sensitive
to changes in cortico-striatal connectivity, which are
known to occur in PD [9]. These data could be used
to build normative models (analogous to “growth
curves”) to determine whether an individual departs
from the normal pattern [10]. If clinically validated,
such approaches may be helpful for diagnosis and
disease monitoring.
A second development could lie in improved func-
tional MRI sequences, enabling brain imaging at a
high temporal and/or spatial resolution. Although
fMRI is thought to be too slow to measure brain
oscillations, given that it depends on slow changes in
blood flow, recent studies have used ultra-rapid fMRI
scanning at 7 Tesla to measure visual cortex BOLD
oscillations at 0.75 Hz following high-frequent visual
stimulation [11]. A further study showed resting
state connectivity at frequencies up to 2.5 Hz [12].
Although it remains to be seen whether these sig-
nals carry information that is different from the
slower BOLD fluctuations, it is possible that future
developments will allow us to measure pathological
oscillations (e.g., tremor) with fMRI. Furthermore,
imaging at both high spatial and temporal resolution
makes it possible to detect abnormal fluctuations in
small brain stem nuclei while adequately correcting
for rapid non-neuronal noise (e.g., cardiac and respi-
ratory fluctuations around the brain stem). Given that
the pathophysiological hallmark of PD is a degener-
ation of several neurotransmitter systems in the brain
stem, these new techniques make it possible to test for
altered activity and functional connectivity of these
nuclei.
STRUCTURAL IMAGING
Structural imaging in PD has made important
advances over the past decade [13], and as we look
to the future several important themes emerge. The
first theme is high-field imaging and improved spatial
resolution having a significant impact on visualiz-
ing and quantifying features of the basal ganglia and
other regions going forward. We are beginning to see
progress in this area already in that 7 Tesla struc-
tural imaging has enabled automated segmentation
of the substantia nigra, subthalamic nucleus, and red
nucleus, which is not available at 3 Tesla [14]. Using
a multimodal protocol, in vivo mapping of the basal
ganglia and thalamic connections was achieved at
submillimetre resolution and included susceptibility
weighted imaging, diffusion imaging, and T1 and T2
weighted imaging [15]. These advances in submil-
limetre structural imaging have not yet made their
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way to routine patient studies but have the potential
to enhance clinical practices such as diagnosing PD
and DBS surgery.
The second theme is in linking diffusion imaging
as a biomarker of differential diagnosis, progression
of PD, and relation to pathology. Recent evidence
has linked diffusion imaging as a predictor of both
cognitive function and motor symptoms in PD [16,
17]. From a methodological perspective, the clas-
sic diffusion tensor imaging model is proving to be
less important when compared with more advanced
computational models for modelling diffusion in the
intracellular and extracellular compartments [18].
The bi-tensor model that can be performed on single-
shell diffusion scans yielding the free-water metric
has shown considerable promise as a biomarker of
progression in early stage PD [19]. There is also some
evidence that examination of free-water in multiple
nodes in the cerebellum and basal ganglia offer key
insights into the degenerative patterns that may dis-
tinguish PD from other forms of Parkinsonism [20].
In addition, other models of diffusion that leverage
multiple shells and more complex mathematics may
also provide new paths to better understanding the
tissue-specific changes in regions that include the
substantia nigra but also nucleus basalis of Meynert,
cerebellum, frontal cortex, brainstem, and many other
structures [21]. Finally, although there is a major
push to develop ligands for PET that will allow neu-
roimaging to directly assay alpha-synuclein, there
is also a case to be made for developing diffu-
sion or other structural imaging markers that may
reflect alpha-synuclein pathology. This is because
there could be considerable structural events (i.e.,
inflammation, neurodegeneration, gliosis) that occur
prior to and after the clinical diagnosis of PD that
are linked to alpha-synuclein pathology, and a multi-
modal approach will prove important in the future.
The final theme is in the area of clinical trials.
At present, phase 1, 2, and 3 clinical trials are not
consistently using structural imaging read-outs for
evaluation. It is the case though that many of the ther-
apies under consideration are not directly affecting
dopamine, and thus having non-invasive structural
imaging assays ready for clinical trial use will prove
important going forward [17].
NUCLEAR IMAGING
A major unsolved problem is the lack of a spe-
cific imaging marker for the pathological hallmark of
PD, alpha synuclein aggregates. There are a num-
ber of reasons for this. First, while many small
aromatic molecules are known to bind to alpha-
synuclein fibrils, they all invariably bind with high
affinity to beta amyloid which can also be present in
elderly PD cases [22, 23]. Second, alpha-synuclein
exists mainly in multiple oligomeric forms only
some of which are toxic [24]. Small molecule lig-
ands tend to bind weakly to these oligomers [25].
Third, alpha-synuclein is subject to multiple post
translational modifications. While high throughput
screening will no doubt continue to identify potential
small molecule PET/SPECT ligands, an alternative
way forward is to develop specific antibodies and pep-
tides to alpha-synuclein oligomers and fibrils. This
research is already in train, although a major problem
is the transport of these ligands across the blood-
brain barrier (BBB). Peptides and vesicles can be
tagged with moieties that bind to BBB transporters,
such as transferrin [26]. However, extraction of these
peptides is still slow relative to the short-lived PET
and SPECT isotopes which have half-lives of minutes
to hours. Other potential approaches may be to: (a)
Design lipophilic cage compounds to passively trans-
port peptide ligands [27]; (b) Use aptamers, which
are circular loops of RNA that can be tailored to bind
specific peptides and transport them across the BBB
[28].
The pathology of PD leads to mitochondrial, lyso-
somal, and proteasomal dysfunction. Small molecule
ligands such as enzyme inhibitors are now becom-
ing available that could act as imaging biomarkers of
these processes. BCPP-FE binds selectively to com-
plex 1 in mitochondria and, in pharmacological doses
acts to reduce mitochondrial membrane potential
[29]. 18F-BCPP-FE has been shown to be a suitable
agent for PET imaging in monkeys and is currently
undergoing human trials. Agents that bind selectively
to lysosomal and proteasomal components are also
being screened as potential imaging markers given
the association between glucocerebrosidase A defi-
ciency and PD. One possible candidate could be the
GBA inhibitor conduritol--epoxide (CBE).
Other fields of development in nuclear imag-
ing include: (1) Surface receptor ligands which are
sensitive to synaptic levels of transmitters. These
already exist for dopamine (11C-raclopride, 11C-
FLB), serotonin (11C-AZ10419369), noradrenaline
(11C-yohimbine), and acetylcholine (18F-FP-TZTP)
but are inhibitors which are relatively insensitive to
changes in transmitter fluxes. More sensitive, possi-
bly agonist markers are required. Specific markers of
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Fig. 1. Potential new imaging methods in Parkinson’s disease. This figure schematically represents new approaches for functional magnetic
resonance imaging (fMRI), structural MRI, and positron emission tomography (PET) imaging.
synaptic function, such as SV2A transporter ligands,
are also under development [30]. 11C-UCB-J is cur-
rently being trialled in PD cases with and without
cognitive deficits. Finally, imaging peripheral sys-
temic changes in PD has become of interest – it
is known alpha-synuclein can be detected in skin
and bowel and that sympathetic and parasympathetic
activity can also be imaged. If a suitable alpha-
synuclein tracer emerges, then peripheral imaging
may help to throw light on the proposal that transmis-
sion of alpha-synuclein aggregates starts peripherally
and proceeds centrally.
CONCLUSION
Parkinson’s disease is a brain disorder with dis-
tinct molecular, functional and structural features.
These characteristics make it a prototypical neuro-
logical disorder where new neuroimaging techniques,
especially the combination of multiple techniques in
single patients [31], have the potential to make sig-
nificant contributions to clinical practice (Fig. 1).
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